Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.11
Views: 9780

Prof Carlo Gambacorti-Passerini - University of Milan Bicocca, Italy

Prof Carlo Gambacorti-Passerini talks about his research into bosutinib as a treatment for patients with Philadelphia chromosome–positive chronic phase chronic myeloid leukaemia. The trial compared bosutinib with imatinib, the current standard therapy for newly diagnosed patients, and patients in the bosutinib group were shown to respond almost twice as quickly as those treated with imatinib. Bosutinib produced similar levels of patient response as other tyrosine kinase inhibitors such as nilotinib and dasatinib but is associated with a lower toxicity profile. Prof Gambacorti-Passerini discusses this difference, talks about the benefits in terms of patient tolerance, safety levels and disease progression but also explains the adverse events encountered by the patients entered into this trial.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation